M Joerger
How to read a next-generation sequencing report-what oncologists need to know.
Schmid S, Jochum W, Padberg B, Demmer I, Mertz K, Joerger M, Britschgi C, Matter M, Rothschild S, Omlin A. How to read a next-generation sequencing report-what oncologists need to know. ESMO Open 2022; 7:100570.
Sep 29, 2022How to read a next-generation sequencing report-what oncologists need to know.
Sep 29, 2022ESMO Open 2022; 7:100570
Schmid S, Jochum W, Padberg Barbara, Demmer I, Mertz K D, Joerger M, Britschgi C, Matter M, Rothschild S I, Omlin Aurelius
LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma.
Gachechiladze M, Überall I, Skanderová D, Matchavariani J, Ibrahim M, Shani I, Smičková P, Kolek V, Cierna L, Kleine-Tebbe J, Stahel R, Joerger M, Soltermann A, Škarda J. LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma. Lung Cancer 2021; 156:129-135.
Apr 15, 2021LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma.
Apr 15, 2021Lung Cancer 2021; 156:129-135
Gachechiladze Mariam, Überall Ivo, Skanderová Daniela, Matchavariani J, Ibrahim M, Shani Ilay, Smičková Petra, Kolek Vítězslav, Cierna L, Kleine-Tebbe Jörg, Stahel R, Joerger M, Soltermann A, Škarda Josef
Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).
Joerger M, Hess D, Delmonte A, Gallerani E, Fasolo A, Gianni L, Cresta S, Barbieri P, Pace S, Sessa C. Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968). Br J Clin Pharmacol 2015; 80:128-38.
Jun 3, 2015Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).
Jun 3, 2015Br J Clin Pharmacol 2015; 80:128-38
Joerger M, Hess D, Delmonte Angelo, Gallerani E, Fasolo A, Gianni L, Cresta S, Barbieri P, Pace S, Sessa C
Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.
Joerger M, Hess D, Delmonte A, Gallerani E, Barbieri P, Pace S, Sessa C. Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors. Invest New Drugs 2015; 33:472-9.
Feb 20, 2015Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.
Feb 20, 2015Invest New Drugs 2015; 33:472-9
Joerger M, Hess D, Delmonte Angelo, Gallerani E, Barbieri P, Pace S, Sessa C
Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
Schmid S, Siano M, Joerger M, Rodriguez R, Müller J, Früh M. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. Lung Cancer 2014; 87:85-7.
Nov 18, 2014Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
Nov 18, 2014Lung Cancer 2014; 87:85-7
Schmid S, Siano Marco, Joerger M, Rodriguez Regulo, Müller J, Früh M
Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study
Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl S, Froehlich T, Largiader C, Joerger M. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother Pharmacol 2012; 71:361-70.
Nov 9, 2012Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study
Nov 9, 2012Cancer Chemother Pharmacol 2012; 71:361-70
Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl St, Froehlich T K, Largiader C R, Joerger M